[O10] Oral Session 10　臓器横断プログラム
【E】

[O10-2] First-in-Human DuoBody^® -CD40x4-1BB (GEN1042) Trial: Safety and Initial Clinical Activity in Advanced Solid Tumors

^○Melissa Johnson¹, Juanita Lopez², Patricia Lorusso³, Jessica Bauman⁴, Daniel Haggstrom⁵, Eleni Lagkadinou⁶, Gaurav Bajaj⁷, Ozlem Tureci⁶, Homer C. Adams Iii⁷, Ugur Sahin⁶, Yali Fu⁷, Tahamtan Ahmadi⁷, Kristoffer S. Rohrberg⁸ (1.Sarah Cannon Research Institute, Nashville, TN, USA, 2.Royal Marsden NHS Foundation Trust, Sutton, UK, 3.Yale Cancer Center, New Haven, CT, USA, 4.Fox Chase Cancer Center, Philadelphia, PA, USA, 5.Levine Cancer Institute, Charlotte, NC, USA, 6.BioNTech SE, Mainz, Germany, 7.Genmab, Princeton, NJ, USA, 8.Department of Oncology, Rigshospitalet, University Hospital of Copenhagen, Copenhagen, Denmark)